Treatment of S antigen uveoretinitis with lipoxygenase and cyclo-oxygenase inhibitors.
The role of metabolites of arachidonic acid (AA) in experimental autoimmune uveoretinitis was studied using inhibitors of AA metabolism. Nordihydroguaiaretic acid (NDGA), which inhibits predominantly the lipoxygenase (LO) pathway, or indomethacin, a specific cyclo-oxygenase (CO) inhibitor, was administered to rats immunized with retinal S antigen. Levels of various AA metabolites were measured in the inflamed uvea, and the severity of intraocular inflammation was quantitated by morphometric analysis. Histopathologically, the uveoretinitis was significantly suppressed following treatment with NDGA, while indomethacin treatment resulted in augmentation of the disease (p less than 0.05). These results tend to indicate that the inhibition of the LO rather than the CO pathway may be more beneficial in the treatment of autoimmune uveitis.
Chen
F
F
Doheny Eye Institute, University of Southern California, Los Angeles.
Pararajasegaram
G
G
Sevanian
A
A
Rao
N A
NA
D000818:Animals; D000886:Anthropometry; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000941:Antigens; D019393:Arrestin; D015232:Dinoprostone / Q000378:metabolism; D004195:Disease Models, Animal; D005136:Eye Proteins; D005260:Female; D007213:Indomethacin / Q000627:therapeutic use*; D007975:Leukotriene B4 / Q000378:metabolism; D009637:Masoprocol / Q000627:therapeutic use*; D011863:Radioimmunoassay; D051381:Rats; D011917:Rats, Inbred Lew; D012173:Retinitis / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D013929:Thromboxane B2 / Q000378:metabolism; D015866:Uveitis, Posterior / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000941:Antigens; D019393:Arrestin; D005136:Eye Proteins; D007975:Leukotriene B4; D013929:Thromboxane B2; D009637:Masoprocol; D015232:Dinoprostone; D007213:Indomethacin